Tumor endothelial markers as a target in cancer

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 12, 2012, Pages 1215-1225

  Ribatti, Domenico ^a   Ranieri, Girolamo ^b   Basile, Antonio ^a   Azzariti, Amalia ^b   Paradiso, Angelo ^b   Vacca, Angelo ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Cancer; Endothelium; Markers; Therapy; Tumor growth

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; CELECOXIB; CM 101; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ENDOSTATIN; FLUOROURACIL; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; HORMONE; IMATINIB; LIGAND; LIPOSOME; METHOTREXATE; MONOCLONAL ANTIBODY; RETINOIC ACID; SEMAXANIB; SUNITINIB; THYMIDINE PHOSPHORYLASE; TUMOR MARKER; VASCULAR CELL ADHESION MOLECULE 1; VATALANIB; VINBLASTINE;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER STEM CELL; CAPILLARY HEMANGIOMA; CELL ADHESION; CIRCULATING ENDOTHELIAL CELL; CIRCULATING ENDOTHELIAL PRECURSOR CELL; CIRCULATING TUMOR CELL; COMPUTER ASSISTED TOMOGRAPHY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MAXIMUM TOLERATED DOSE; NANOMEDICINE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PROMYELOCYTIC LEUKEMIA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEM CELL; TUMOR RESISTANCE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL ADHESION MOLECULES; DEOXYCYTIDINE; ENDOTHELIAL CELLS; FLUOROURACIL; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; NEOPLASTIC STEM CELLS; RECEPTORS, GROWTH FACTOR; THYMIDINE PHOSPHORYLASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84869457543     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.725047     Document Type: Review

References (115)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29(6 Suppl 16):15-18
2. Ribatti D, Nico B, Crivellato E, et al. The history of the angiogenic switch concept. Leukemia 2007;21:44-52
3. Ribatti D. The discovery of endothelial progenitor cells. An historical review. Leukemia Res 2007;31:439-44
4. Maniotis AJ, Folberg R, Hess AR, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999;155:739-52
5. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8
6. Ribatti D, Djonov V. Intussusceptive microvascular growth in tumors. Cancer Lett 2012;316:126-31
7. Schlingemann RO, Oosterwijk E, Wesseling P, et al. Aminopeptidase a is a constituent of activated pericytes in angiogenesis. J Pathol 1996;179:436-42
8. Marchio S, Lahdenranta J, Schlingemann RO, et al. Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell 2004;5:151-62
9. Saiki I, Fujii Y, Yoneda F, et al. Role of aminopeptidase N. (CD 13) in tumor cell invasion and extracellular matrix degradation. Int J Cancer 1993;54:137-43
10. Sato M, Arap W, Pasqualini R. Molecular targets on blood vessels for cancer therapies in clinical trials. Oncology (Williston Park) 2007;21:1346-52
11. Hatakeyama S, Sugihara K, Shibata TK, et al. Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide. Proc Natl Acad Sci USA 2011;108:19587-9
12. Yan M, Callahan CA, Beyer JC, et al. Chronic DLL4 blockade induces vascular neoplasms. Nature 2010;463:E6-7
13. Koutsioumpa M, Drosou G, Mikelis C, et al. Pleiotrophin expression and role in physiological angiogenesis in vivo: potential involvement of nucleolin. Vasc Cell 2012;4:4
14. Stafford JH, Thorpe PE. Increased exposure of phosphatidylethanolamine on the surface of tumor vascular endothelium. Neoplasia 2011;13:299-308
15. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569-71
16. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80
17. Laubli H, Borsig L. Selectins promote tumor metastasis. Semin Cancer Biol 2010;20:169-77
18. Burrows FJ, Derbyshire EJ, Tazzari PL, et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995; 5:2674-81
19. Seon BK. Expression of endoglin (CD105) in tumor blood vessels. Int J Cancer 2002;99:310-11
20. Brekken RA, Thorpe PE. Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res 2001;21:4221-9
21. Nillson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B-domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001;61:711-16
22. Chang SS, O'Keefe DS, Bacich DJ, et al. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5:2674-81
23. Dejana E, Giampietro C. Vascular endothelial-cadherin and vascular stability. Curr Opin Hematol 2004;19:218-23
24. Martin-Padura I, Bertolini F. Circulating endothelial cells as biomarkers for angiogenesis in tumor progression. Front Biosci (Schol Ed) 2009;1:304-18
25. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptors, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24
26. Klement GL, Yip TT, Cassiola F, et al. Platelets actively sequester angiogenesis regulators. Blood 2009;113:2835-42
27. Cervi D, Yip TT, Bhattacharya N, et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 2008; 111:1201-7
28. Ranieri G, Coviello M, Patruno R, et al. Vascular endothelial growth factor concentrations in the plasma-activated platelets rich (P-APR) of healthy controls and colorectal cancer patients. Oncol Rep 2004;12:817-20
29. Chang E, Boyd A, Nelson CC, et al. Successful treatment of infantile hemangiomas with interferon alpha-2b. Pediatr Hematol Oncol 1997;19:237-44
30. Kumar H, Heer K, Greenman J, et al. Soluble FLT-1 is detectable in the sera of colorectal and breast cancer patients. Anticancer Res 2002;22:1877-80
31. Norden-Zfoni A, Desai J, Manola J, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007;13:2643-50
32. Byrne GJ, Ghellal A, Iddon J, et al. Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst 2000;92:1329-36
33. Herbst RS, Hess KR, Tran HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002; 20:3792-803
34. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 2005;16:558-65
35. Kuenen BC, Levi M, Meijers JC, et al. Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. Clin Oncol 2003;21:2192-8
36. Dowlati A, Robertson K, Radivoyevitch T, et al. Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Clin Cancer Res 2005;11:7938-44
37. DeVore RF, Hellerqvist CG, Wakefield GB, et al. Phase I study of the antineovascularization drug CM101. Clin Cancer Res 1997;3:365-72
38. Stempak D, Gammon J, Halton J, et al. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol 2006;28:720-8
39. Gao D, Nolan DJ, Mellick AS, et al. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008;319:195-8
40. De Palma M, Venneri MA, Galli R, et al. Tie 2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005;8:211-26
41. Rajantie I, Ilmonen M, Alminaite A, et al. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 2004;104:2084-6
42. Song S, Ewald AJ, Stallcup W, et al. PDGFRbeta+ prerivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005;7:870-9
43. Yang L, DeBusk LM, Fukuda K, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004;6:409-21
44. Cornejo-Garcia JR, Benencia F, Courregas MC, et al. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of VEGF-A. Nat Med 2004;10:950-8
45. Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006;124:175-89
46. G-One A, Brown JM. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008;13:193-205
47. Mancuso P, Burlini A, Pruneri G, et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001;97:3658-61
48. Zhang H, Vakil V, Braunstein M, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005;105:3286-94
49. Furstenberger G, von Moos R, Lucas R, et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 2006;94:524-31
50. Mancuso P, Colleoni M, Calleri A, et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006;108:452-9
51. Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003;63:4342-6
52. Rafii S, Lyden D, Benezra R, et al. Vascular and haemopoietic stem cells: novel targets for anti-angiogenesis therapy. Nat Rev Cancer 2002;2:826-35
53. Monestiroli S, Mancuso P, Burlini A, et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 2001;61:4341-4
54. Capillo M, Mancuso P, Gobbi A, et al. Continuous infusion of endostatin inhibits differentiation, mobilization and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 2003; 9:377-82
55. Taylor M, Rossler J, Geoerger B, et al. High levels of circulating VEGFR2+ bone marrow-derived progenitor cells correlate with metastatic disease in patients with pediatric solid malignancies. Clin Cancer Res 2009;15:4561-71
56. Vroling L, van der Veldt AA, de Haas RR, et al. Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib. Angiogenesis 2009;12:69-79
57. Greenfield JP, Jin DK, Young LM, et al. Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme. Neurosurgery 2009;64:819-26
58. Ranieri G, Roccaro AM, Vacca A, Ribatti D. Thymidine phosphorylase (platelet-derived endothelial cell growth factor) as a target for capecitabine: from biology to the bedside. Recent Pat Anticancer Drug Discov 2006;1:171-83
59. Passantino L, Patruno R, Valerio P, et al. Thymidine phosphorylase profiles in nonmalignant and malignant pancreatic tissue. Potential therapeutic role of capecitabine on tumoral and endothelial cells and tumor-infiltrating macrophages. Immunopharmacol Immunotoxicol 2005;27:95-107
60. Ranieri G, Grammatica L, Patruno R, et al. A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients. J Cell Mol Med 2007;11:362-8
61. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11:69-82
62. Stupp R, Hegi ME. Targeting brain-tumor stem cells. Nat Biotechnol 2007;25:193-4
63. Ricci-Vitiani L, Pollini R, Biffoni M, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010;468:824-8
64. Wang R, Chadalovada K, Wilshire J, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010;468:829-33
65. Bao SD, Wu QL, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006;66:7843-8
66. Deininger M, Buchdunger E, Druker BJ. The development of inatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640-53
67. Holtz MS, Forman SJ, Bhatia R. Nonproliferating CML CD44+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 2005;19:1034-41
68. Jin L, Hope KJ, Zhai Q, et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006;12:1167-74
69. Tavor S, Petit I, Porozov S, et al. CXCR4 regulates migration and development of human acute myelogeneous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 2004;64:2817-24
70. Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour infiltrating cells. Nature 2006;444:761-5
71. Hovinga KE, Shimizu F, Wang R, et al. Inhibition of Notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 2010;28:1019-29
72. Spira AI, Carducci MA. Differentiation therapy. Curr Opin Pharmacol 2003;3:338-43
73. Camacho LH. Clinical application of retinoids in cancer medicine. J Biol Regul Homeost Agents 2003;17:98-114
74. Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 2003;17:1454-63
75. Andreeff M, Jiang S, Zhang X, et al. Expression of bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 1999;13:1881-92
76. Dobrucki LW, Sinusas AJ. Imaging angiogenesis. Curr Opin Biotech 2007;18:1-7
77. Ma X, Tian J, Yang X, et al. Molecular imaging in tumor angiogenesis and relevant drug research. Int J Biomed Imaging 2011;2011:370701
78. Lu X, Wang RF. A concise review of current radiopharmaceuticals in tumor angiogenesis imaging. Curr Pharm Des 2012;18:1032-40
79. Mulder WJ, van der Schaft DW, Hautvast PA, et al. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J 2007;21:378-83
80. Klibanov AL. Ligand-carrying gas-filled microbubbles: ultrasound agents for targeted molecular imaging. Bioconjug Chem 2005;16:9-17
81. Bauer A, Bartl R, Pellengahr M, et al. Neovascularization of bone marrow in patients with diffuse multiple myeloma: a correlative study of magnetic resonance imaging and histopathologic findings. Cancer 2004;101:2599-604
82. Shih TT, Tien HF, Liu CY, et al. Functional MR imaging of tumor angiogenesis predicts outcome of patients with acute myeloid leukaemia. Leukemia 2006;20:357-62
83. Spear MA, LoRusso P, Mita A, et al. Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic. Curr Drug Targets 2011;12:2009-15
84. Hollbecque A, Massard C, Soria JC. Vascular disrupting agents: a delicate balance between efficacy and side effects. Curr Opin Oncol 2012;24:305-15
85. Sergeeva A, Kolonin M G, Molldrem JJ, et al. Display technologies: application for the discovery of drug and gene delivery agents. Adv Drug Deliv Rev 2006;58:1622-54
86. Pastorino F, Brignole C, Marimpietri D, et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 2003;63:7400-9
87. Curnis F, Arrigoni G, Sacchi A, et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 2002;62:867-74
88. Corti A, Curnis F. Tumor vasculature targeting through NGR peptide-based drug delivery systems. Curr Pharm Biotechnol 2011;12:1128-34
89. O'Connell PJ, Gerkis V, d'Apice AJ. Variable O-glycosylation of CD13 (aminopeptidase N). J Biol Chem 1991;266:4593-7
90. Colombo G, Curnis F, De Mori GM, et al. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem 2002;277:47891-7
91. Levchenko TS, Hartner WC, Torchillin VP. Liposomes for cardiovascular targeting. Ther Deliv 2012;3:501-14
92. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24
93. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9
94. Jain RK. The next frontier of molecular medicine: delivery of therapeutics. Nat Med 1998;4:655-7
95. Pastorino F, Brignole C, Di Paolo D, et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 2006;66:10073-82
96. Pastorino F, Di Paolo D, Piccardi F, et al. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin Cancer Res 2008;14:7320-9
97. Garde SV, Forte AJ, Ge M, et al. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anticancer Drugs 2007;18:1189-200
98. Gabizon A, Isacson R, Rosengarten O, et al. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol 2008;61:695-702
99. Allen TM, Cheng WW, Hare JI, Laginha KM. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med Chem 2006;6:513-23
100. Parhi R, Suresh P. Preparation and characterization of solid lipid nanoparticles-a review. Curr Drug Discov Technol 2012;9:2-16
101. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002;2:750-63
102. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 2002;62:7190-4
103. Taatjes DJ, Koch TH. Nuclear targeting and retention of anthracycline antitumor drugs in sensitive and resistant tumor cells. Curr Med Chem 2001;8:15-29
104. Elayadi AN, Samli KN, Prudkin L, et al. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for non small cell lung cancer. Cancer Res 2007;67:5889-95
105. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996;380:364-6
106. Staquicini FI, Sidman RL, Arap W, et al. Phage display technology for stem cell delivery and systemic therapy. Adv Drug Deliv Rev 2010;62:1213-16
107. Li L, Wartchow CA, Danthi SN, et al. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Inter J Radiation Oncol Biol Phys 2004;58:1215-27
108. Mc Carthy JR, Bhaumik J, Karver MR, et al. Targeted nanoagents for the detection of cancers. Mol Oncol 2010;4:511-28
109. Temming K, Schiffelers RM, Molema G, Kok RJ. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resistence Updates 2005;5:381-402
110. Arosio D, Casagrande C, Manzoni L. Integrin-mediated drug delivery in cancer and cardiovascular diseases with Peptide-functionalized nanoparticles. Curr Med Chem 2012;19:3128-51
111. Teicher BA. Antibody-drug conjugate targets. Curr Cancer Drug Targets 2009;9:982-1004
112. Pasquetto MV, Vecchia L, Covini D, et al. Targeted drug delivery using immunoconjugates: principles and applications. J Immunother 2011;34:611-28
113. Casi G, Neri D. Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release 2012;161:422-8
114. Adair JR, Howard PW, Hartley JA, et al. Antibody-drug conjugates-a perfect synergy. Expert Opin Biol Ther 2012;12:1191-206
115. Lin K, Tibbitts J. Pharmakocinetics considerations for antibody drug conjugates. Pharm Res 2012;29:2354-66